Compare DexCom, Inc. (DXCM) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nike Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Nike Inc trades at $34.71 (market cap $51.60B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays a 4.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Nike Inc for 155 Days on average.
| DXCM | NKE | |
|---|---|---|
Market Cap | $31.86B | $51.60B |
Volume | 3,607,070 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $69.68 |
52-Week Low | $54.84 | $33.87 |
Typical Hold Time | 62 Days | 155 Days |
Enterprise Value | $31.32B | $54.30B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Nike (NKE) trades at $34.74, up 1.11% with bearish technical signals despite recent earnings beats. The company faces revenue pressure with FY2025 sales declining to $46.31B and net margin compressing to 6.74%. Analyst consensus remains positive with a $36.98 price target, though technical indicators show 16 sell signals against 2 buy signals. Recent news highlights challenges in China and EMEA markets while emphasizing Nike's strong brand positioning.
Nike's investment case balances strong brand equity against near-term operational headwinds. The stock offers value at 16.62 P/E with 21.56% ROE, but investors face risks from sluggish consumer demand and margin pressure. The upcoming Q4 2026 earnings on June 30 will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
